<DOC>
	<DOCNO>NCT00718679</DOCNO>
	<brief_summary>This study placebo control , double blind , randomise , two arm dose escalation new product specific immunotherapy cat allergic patient</brief_summary>
	<brief_title>Evaluation Safety , Tolerability , Immunogenicity Efficacy Novel Method Specific Immunotherapy Cat Allergic Patients : Placebo Controlled Trial</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : History subjective symptom cat dander allergy include cat specific allergic rhinitis Age 18 65 year Positive reaction least one concentration cat dander allergen skin prick test , intradermal provocation test nasal provocation test Exclusion criterion : Chronic infectious disease Acute infection Episode nonallergic rhinitis within last 4 week Use allergen know predict anaphylactic reaction Treatment investigational drug within 3 month trial entry Vaccination within last week Nasal surgery within last 8 week Progressive fatal disease Drug alcohol abuse within last 5 year Cat ownership A history significant cardiac insufficiency ( NYHA stage IIIIV ) Coexisting severe disease , e.g . cardiovascular disease Acute history obstructive respiratory insufficiency ( FEV1 &lt; 70 % ) Hepatic insufficiency Relevant anaemia ( judged investigator ) Blood donation within last 30 day intend blood donation ( study 30 day participation ) Pregnancy breast feed Sexually active woman childbearing potential actively practice birth control use medically accept device therapy Lack compliance sililar reason , investigator believe , preclude satisfactory participation study Systemic glucocorticoid therapy Allergic asthma chronic medication steroid dose exceed 200ug/day Treatment ATII antagonist , Bblocker , ACE inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>